Antioedematous agents and diuretics (A61P7/10)

A   Human necessities(312083)
A61P7/10                     Antioedematous agents; diuretics(75)
Drug with spasmolithic, diuretic and lithiolic action // 2635459
FIELD: pharmacology.SUBSTANCE: agent containing belladonna alkaloids, tincture of European madder, magnesium salicylate, a mixture of essential oils with a set of active substances, salicylic acid, linoleic and linolenic acids, ethanol and castor oil is proposed, wherein the substance contains the sum of belladonna alkaloids, recalculated for hyoscyamine as belladonna alkaloids, eucalyptus essential oil, anise essential oil and fennel essential oil as essential oils, and 1,8-cineole eucalyptus essential oil as a biologically active substance with a certain content of the ingredients.EFFECT: pronounced therapeutic effect in pain elimination and excretion of urinary stones, pronounced anti-inflammatory and diuretic effects.3 ex
Drug with litholithic, diuretic and anti-inflammatory action // 2635196
FIELD: pharmacology.SUBSTANCE: preparation containing a tincture of European madder root, magnesium salicylate, essential oils with a set of active substances, ethyl alcohol and vegetable oil is proposed, the composition further comprises a mixture of linoleic and linolenic acids, castor oil as a vegetable oil, eucalyptus essential oil, anise essential oil and fennel essential oil as essential oils, and 1,8-cineole eucalyptus essential oil as a biologically active substance of essential oils a at certain ratio of the composition ingredients.EFFECT: pronounced therapeutic effect in destruction and excretion of urinary stones, pronounced anti-inflammatory and diuretic effects.2 cl, 4 ex
Agents with diuretic activity // 2619350
FIELD: pharmacology.SUBSTANCE: diuretic contains 0.5% solution of humic acids and magnesium chloride, taken in a certain ratio.EFFECT: means allows to increase therapy effectiveness and eliminates occurrence of side effects.3 ex
Agent with diuretic activity // 2619349
FIELD: pharmacology.SUBSTANCE: diuretic contains 0.5% solution of humic acids and zinc chloride, taken in a certain ratio.EFFECT: means allows to increase therapy effectiveness and eliminates occurrence of side effects.3 ex
Diuretic // 2619348
FIELD: pharmacology.SUBSTANCE: diuretic contains 0.5% solution of fulvic acids and magnesium chloride, taken in a certain ratio.EFFECT: means allows to increase therapy effectiveness and eliminates occurrence of side effects.3 ex
Diuretic // 2619346
FIELD: pharmacology.SUBSTANCE: diuretic contains 0.5% solution of humic acids and silver chloride, taken in a certain ratio.EFFECT: means allows to increase therapy effectiveness and eliminates occurrence of side effects.3 ex

Vegetable combined preparations based on dry extracts // 2599515
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, particularly to a preparation possessing diuretic and/or antibacterial and/or litholytic action. Preparation possessing diuretic and/or antibacterial and/or litholytic action, containing dry alcoholic extract of rosehips grass and root of wild rose, as well as auxiliary substances. Above described preparation extends the range of herbal combined preparations, suitable for use as a diuretic, antibacterial and litholytic agents.EFFECT: preparation has high effect in comparison with use of mono preparations.7 cl, 9 dwg, 11 tbl

Inhibitor of liquid in cavities of body accumulation // 2597795
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and concerns drug for inhibiting accumulation of liquid into mammals body cavity, having accumulation of liquid in cavity of body, caused by cancer, as active substance containing covalent conjugate of interferon-beta with polyethylene glycol.EFFECT: invention provides effective treatment and removal of liquid from body cavity by systemic administration as well as by local administration.9 cl, 6 dwg, 6 ex

ethod of producing nonapeptides // 2592282
FIELD: chemistry. SUBSTANCE: invention relates to a solid-phase method of producing nonapeptides of the following formula I-III: R - A r g 1 - L y s 2 - L y s 3 - T y r 4 - L y s 5 - T y r 6 - A r g 7 - X a a 8 - L y s 9 - N H 2 ,where R=H, Xaa=L-Arg (I); R=Me, Xaa=L-Arg (II); R=H, Xaa=D-Axg (III). Nonapeptides synthesis as per formula I-III is carried out by serial growth of the peptide chain, starting with the C-terminal amino acid covalently bound with the polymer matrix using Nα-protected derivatives of arginine, for blocking the guanidine function of which protonating is used. For the guanidine function protonation 1-hydroxybenzotriazole, hexafluorophosphate or tetrafluoroborate is used. Obtained nonapeptidilpolymer is processed with an unblocking agent for removing the protective groups and the polymeric matrix and in 1 stage the end product is given out by means of HELC. EFFECT: method increases the output of end products, simplifies and lowers the cost of their production process. 4 cl, 5 dwg, 5 tbl, 3 ex

Fatty acid fumarate derivatives and uses thereof // 2588256
FIELD: chemistry.SUBSTANCE: invention relates to novel compounds of formula I or pharmaceutically acceptable salts thereof, enantiomers or stereoisomers; in which values for groups W1, W2, R3, L, Z, a, b, m, c, d, etc. are defined in patent claim.EFFECT: invention also refers to pharmaceutical compositions based on said compounds possessing inhibitory activity on NF-kB, for treating inflammation or inflammatory disease, type II diabetes, insulin-resistant cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dislipidemia, retinopathy, neuropathy, macular edema, diabetic nephropathy, IgA nephropathy, CLD, inflammatory diseases of kidneys.25 cl, 4 dwg, 25 ex, 1 tbl

Costmary syrup // 2578980
FIELD: medicine.SUBSTANCE: invention relates to tansy syrup possessing potassium-sparing effect. Syrup contains 10.0 wt% infusion of tansy flowers, 55.8 wt% sorbitol or fructose, and 34.2 wt% of purified water. Infusion of tansy flowers produced by modified maceration comprising triple extraction of plant material distributed on three percolators in equal amounts of 40% ethyl alcohol in a ratio of raw material - extractant is 1:5, where last stage of each percolator is conducted under heating in a water bath for 30 minutes.EFFECT: invention is characterised by optimum composition and a higher content of active ingredients in comparison with analogues.1 cl, 2 dwg, 2 ex

ilk-gowan syrup // 2577713
FIELD: medicine.SUBSTANCE: invention relates to milk gowan syrup possessing diuretic effect. Syrup contains 10.0 WT% or 5.0 WT% of tincture from milk gowan, 55.8 WT% or 58.9 WT% of sorbitol and 34.2 WT% or 36.1 WT% of purified water, respectively. Note here that said milk gowan tincture is produced by modified maceration, including triple extraction of vegetal raw materials distributed in three percolators in equal quantities, 40 % or 70 % ethanol in ratio of raw material: extractant 1:5, where the last stage in each percolator is carried out while heating on a water bath for 30 minutes.EFFECT: invention is characterised by high output of the active substances.1 cl, 1 dwg, 4 ex
Pharmaceutical substance of salt of l-lysine amino acid and escin // 2569353
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to field of pharmaceutics and medicine and deal with pharmaceutical substance, which represents salt of L-lysine amino acid and escin, with escin representing mixture of escin Ia, escin Ib, isoescin Ia and isoescin Ib, where ratios of escin Ia and escin Ib sum to isoescin Ia and isoescin Ib sum constitutes 1.0-4.0:4.0-1.0, preferably 3:2. Pharmaceutical composition, containing said substance, possesses anti-oedematous and anti-inflammatory action.EFFECT: group of inventions provides safe therapeutic profile with reduced frequency of development of side effects.3 cl, 5 ex, 6 tbl

odulation of aquaporins with relaxin // 2564900
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to medicine and deal with application of pharmaceutically activated relaxin H2 for obtaining medication for treatment of nephrogenic diabetes insipidus in subject, requiring it. Group of inventions also deal with application of pharmaceutically active relaxin H2 for treatment of nephrogenic diabetes insipidus in subject, requiring it.EFFECT: group of inventions provides relaxation or reduction of excessive production of diluted urine and accompanying complications, associated with nephrogenic diabetes insipidus.14 cl, 5 ex, 11 dwg, 2 tbl
Filtration composition and method for fat excision // 2540497
FIELD: medicine.SUBSTANCE: invention represents a composition for surgical area infiltration in liposuction or lymphedema elimination, containing normal saline, 0.5% Naropin and phosphatidylcholine in ratio 9:1:6 respectively per 10-15 cm3 fat.EFFECT: reducing oedema, tissue injuries and blood loss volume, preventing microcirculation disorders in soft tissues and complications, reducing a risk of recurrences and promoting a faster rehabilitation of the patients.2 cl

4-hydroxy-n-(2-carboxyphenyl)-1-methyl-2,2-dioxo-1h-2λ6,1-benzothiazine-3-carboxamide, demonstrating diuretic activity // 2535997
FIELD: chemistry.SUBSTANCE: invention relates to 4-hydroxy-N-(2-carboxyphenyl)-1-methyl-2,2-dioxo-1H-2λ6 ,1-benzothiazine-3-carboxamide, which possesses diuretic activity.EFFECT: obtained is novel compound, possessing useful biological activity.1 tbl, 3 ex

Agent having diuretic and anti-inflammatory action // 2522925
FIELD: biotechnology.SUBSTANCE: agent is proposed which has diuretic and anti-inflammatory action. It is shown that the sodium salt of 4-carboxyphenyl-O-β-D-glucopyranoside increased the daily diuresis 2 times or more, at that the excretion of sodium and potassium ions is reduced compared to the control; its anti-inflammatory activity is slightly higher than that of nimesulide. Due to the combination of the diuretic effect with anti-inflammatory and antimicrobial activities the agent can be used for the treatment of nephritis, pyelonephritis, cystitis of stagnant phenomena in the systemic and pulmonary circulation due to heart failure.EFFECT: increased water excretion thus contributing to reduction of swelling.2 tbl

edication, possessing diuretic action // 2517091
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutics, namely to application of P-methyl-phenyl-O-D-glucopyranoside as medication, which has a diuretic action, which has high diuretic and low saluretic activity.EFFECT: obtaining medication, which has a diuretic action, which has high diuretic and low saluretic activity.1 tbl, 1 ex

Diuretic agent // 2500407
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmacology, namely to using "П"-methyl-phenyl-O-D-glucopyranoside as an agent possessing high diuretic and low saluretic activity.EFFECT: preparing the diuretic drug possessing high diuretic and low saluretic activity.1 tbl, 1 ex

Amide of nonapeptide preventing increase of hyperpermeability of vessel endothelium // 2493164
FIELD: biotechnologies.SUBSTANCE: peptide of the formula H-(N-Me)-Arg-Lys-Lys-Tyr-Lys-Tyr-Arg-D-Arg-Lys-NH2 is proposed. The proposed peptide may find application as an agent for reduction of pathological hyperpermeability of vessel endothelium in various areas of medicine (in cardiology, toxicology, neurosurgery, oncology, etc.).EFFECT: prevention of sharp increase of vessel endothelium permeability when injected to a recipient.3 cl, 4 dwg, 1 tbl, 5 ex

ethod of obtaining vegetable preparation, which has diuretic and anticoagulation activity // 2491951
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and deals with creation of medication of vegetable origin based on biologically active substances of Linaria vulgaris, which has diuretic and anticoagulation activity. Method of obtaining medication, which has diuretic and anticoagulation activity, consists in the following: extraction of milled grass of Linaria vulgaris with ethyl alcohol is carried out with successive drawing with 3 parts of extractant by method of remaceration with heating and connecting vacuum at the stage of discharge, under specified conditions.EFFECT: method makes it possible to obtain medication, which has high diuretic and anticoagulation activity.3 tbl, 1 ex

Diuretic agent // 2487714
FIELD: medicine, pharmaceutics.SUBSTANCE: what is presented is an agent of diuretic action of a group of aquaretics, phenyl-α-O-D- glucopyranoside. The agent may be used both to treat greater and lesser circulation congestions caused by cardiac failure, and to intensify water release thereby helping to reduce oedemas. The agent has high and low saluretic activity unlike the existing diuretics and expands the range of products of synthetic origin possessing diuretic activity.EFFECT: agent is applicable for treating the number of cardiovascular diseases accompanied by excessive hydration and developing oedema syndrome.1 tbl

Diuretic agent // 2484826
FIELD: medicine, pharmaceutics.SUBSTANCE: what is presented is a diuretic of the aquaretic group that is 4-nitro-phenyl-O-D-glucopyranoside. The agent may be used both to treat greater and lesser circulation congestions caused by cardiac failure, and to intensify water release thereby helping to reduce oedemas. The diuretic agent has high and low saluretic activity unlike the existing diuretics and expands the range of products of synthetic origin possessing diuretic activity.EFFECT: agent is applicable for treating a number of cardiovascular diseases accompanied by excessive hydration and developing oedema syndrome.1 tbl

Pharmaceutical solid preparation containing benzazepin and method for preparing it // 2466717
FIELD: medicine.SUBSTANCE: what is described is a new pharmaceutically solid preparation of a vasopressin antagonist which contains: (a) 7-chlor-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro- 1H-benzoazepine and/or its salt; (b) hydroxypropylcellulose containing a hydroxypropoxyl group in the amount of 50% or more; and (c) at least one of the ingredients specified in a group consisting of carmellose, sodium carboxymethyl starch, crospovidone and hydroxypropylcellulose with a lower degree of substitution with an average diameter of particles 30 to 70 mcm and 90% of the cumulative diameter of 100 to 200 mcm.EFFECT: pharmaceutical solid preparation shows excellent desintegration properties and solubility leading to adequate gastrointestinal absorbability of the active ingredients.17 cl, 4 tbl, 21 ex

Benzimidazole derivatives, based pharmaceutical composition and methods of using them // 2456276
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to new benzimidazole derivatives of general formula (I) or to its pharmacologically acceptable salts wherein R1 represents a C6-aryl group which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), or a heterocyclic group which represents pyridyl, dihydrobenzofuranyl, 1,3-benzodioxolyl, tetrahydropyranyl, tetrahydrofuranyl which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), R2 represents a C1-C6 alkyl group, R3 represents a C6-aryl group which can be substituted by 1-2 groups optionally specified in a group of substitutes (a), Q represents a group represented by formula =CH-, or a nitrogen atom and a group of substitutes (a) represents a group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a carboxyl group, a C2-C7 alkylcarbonyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, an amino group, a 4-morpholinyl group and a di-C1-C6 alkyl)amino group. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I), to a PPARγ activator/modulator based on the compound of formula (I), to using the compound of formula (I), to a method of reducing blood glucose, to a method of activating PPARγ, a method of treating and/or preventing said pathological conditions.EFFECT: there are produced new benzimidazole derivatives showing PPARγ modulatory activity.41 cl, 2 dwg, 6 tbl, 76 ex
Diuretic // 2456002
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to experimental medicine, namely to pharmacology. The object in view is achieved by the fact that 0.5% humic acids additionally containing magnesium sulphate (II) are applied as a diuretic in the following proportions: 0.5% humic acids - 40 ml; magnesium sulphate - 0.1 g.EFFECT: higher clinical effectiveness and eliminated side effects.1 cl, 1 ex
Potassium uretic peptide // 2454426
FIELD: chemistry.SUBSTANCE: invention relates to therapeutically active chemical compounds which influence uriniparous activity of kidney and specifically a peptide which causes selective increase in release of potassium ions by kidneys.EFFECT: obtaining a compound for treating hyperkalaemia.1 cl, 2 tbl, 2 ex

Cyclic nonapeptide showing ability to inhibit myosin light chain kinase // 2443710
FIELD: medicine.SUBSTANCE: invention refers to biologically active peptides able to inhibit myosin light chain kinase and thereby regulate the variability of vascular endothelial permeability. What is offered is a cyclic nonapeptide of formula cyclo[-Arg-Lys-Lys-Tyr-Lys-Tyr-Arg-Arg-Lys-].EFFECT: peptide can find application as a decongestant in various fields of medicine.2 dwg, 2 ex

ethod of treating distal postmastectomy lymphedema // 2435577
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to surgery and can be used for treatment of distal postmastectomy lymphedema. For this purpose at the background of standard treatment 6 procedures of retrograde lymphotropic introduction of drug mixture are carried out. Lymphotropic introduction is performed in the following way: in area of middle third of forearm applied is cuff, with creating in it pressure of 60 mm Hg, after which in two points on internal surface in area of wrist introduction of mixture of medications is performed. Composition of introduced mixture alternates every second day: 1, 3, 5 days - actovegin 80 mg, ketonal 1 ml, marcaine 0.5% 4 ml; 2, 4, 6 days - chymotrypsin 100 mg, marcaine 0.5% 4 ml.EFFECT: method ensures efficient treatment of postmastectomy lymphedema due to enhancing of lymphatic drainage of distal parts of extremity.3 tbl, 2 ex, 1 dwg
Diuretic // 2408367
FIELD: medicine, pharmaceutics.SUBSTANCE: there is offered the administration of the preparation Histochrome (echinochrome, 2,3,5,6,8-pentahydroxy-7-ethyl-1,4-nahthochine, formerly known as an antioxidant) as a diuretic.EFFECT: histochrome exhibits an evident diuretic action equal thiazide-type diuretics in intensity, does not cause associated hypokaliemia, has an absolute advantage over thiazide-type diuretics.2 tbl

Nonapeptide amide, possessing ability to prevent increase of vessel endothelium permeability // 2402565
FIELD: medicine.SUBSTANCE: invention relates to biologically active peptides, able to prevent sharp increase of permeability of vessel endothelium. Claimed is peptide of formula H-(N-Me)-Arg-Lys-Lys-Tyr-Lys-Tyr-Arg-Arg-Lys-NH2 and its pharmaceutically acceptable salts.EFFECT: peptide can be applied as anti-edema medication in various fields of medicine.1 dwg, 2 ex

Synthetic peptides reducing or eliminating baggy lower eyelids, and application thereof in cosmetic or dermopharmaceutical compositions // 2387666
FIELD: medicine.SUBSTANCE: invention relates to peptides of general formula , and to their cosmetically or dermopharmaceutically acceptable salts, where: X is chosen from the group formed by cysteinyl, seryl, threonyl and aminobutyryl; R1 is chosen from the group formed by H or a saturated linear C2-C24 acyl group; R2 is chosen from the group formed by an amino group optionally substituted with C1-C24 alkyl, or a hydroxy group. Besides the invention covers a method for making said peptides, their cosmetic or dermopharmaceutical compositions intended for reducing or eliminating baggy lower eyelids.EFFECT: higher effectiveness.12 cl, 7 ex

ethod of urinary normalisation in renal malfunction // 2367442
FIELD: medicine.SUBSTANCE: invention refers to pharmaceutical compound to improve renal function that contains KW-3902 30 mg or its pharmaceutically acceptable salt, ester, amide, and furosemide. Also there are disclosed method to induce diuretic effect, method to improve renal function, method to support renal function and method to recover renal function in a patient.EFFECT: effective recovery of renal function in patients with congestive heart failure.13 cl, 2 tbl, 7 ex

1-deoxy-1-n-methyl ammonium-d-glucitole succinate // 2345060
FIELD: chemistry, pharmaceutics.SUBSTANCE: invention relates to novel chemical composition from group quaternary ammonium salts of succinic acid, namely, 1-deoxy-1-N-methyl ammonium-D-glucitole succinate (meglumine succinate) .EFFECT: obtaining chemical composition which acquires ability to impact on complex of pathological changes accompanying sugar diabetes.4 cl, 6 tbl
ethod for treating edema of the upper limbs // 2320332
FIELD: medicine, surgery.SUBSTANCE: into area of brachial plexus due to inter-scalene access one should introduce medicinal mixture that contains 2 ml 2%-lidocaine solution, 0.2 ml 0.05%-proserine solution and 3 ml physiological solution. Injection could be also fulfilled due to axillary access. Before injection it is necessary to carry out electrodiagnostics. Thus, at the first stage one should introduce an electrodiagnostic needle into the axilla at the angle of 45 against skin, towards the caput of brachial bone to affect with the current at power being 1 mA, frequency of 2 Hz till the onset of muscular contractions. After that current power should be decreased up to 0.5 mA. Due to moving the needle mentioned, in case of muscular response it is important to inject medicinal mixture. At the second stage one should introduce the electrodiagnostic needle into area of intersection of imaginary line that connects the end of cricoid cartilage with a spinous process of the 6th cervical vertebra with inter-scalene sulcus, in direction 40-45 towards sagittal and frontal planes, for the depth of 0.5-1 cm. One should affect with current power of 1 mA till the onset of muscular contractions. After that current power should be decreased up to 0.5 mA. Due to moving the needle, in case of muscular response it is necessary to inject medicinal mixture. The procedure described should be fulfilled thrice, at 48-h-long interval. The innovation improves interstitial drainage due to creating the effect of "muscular pump".EFFECT: higher efficiency of therapy.1 ex, 3 tbl

Optically active derivatives of dihydropyridine, their using and therapeutic agent based on thereof // 2294328
FIELD: organic chemistry, medicine, cardiology.SUBSTANCE: invention relates to (R)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridine dicarboxylic acid 3-(1-diphenylmethylazethidin-3-yl) 5-isopropyldiester of the formula (I): or its pharmacologically acceptable salts. Indicated compounds possess antagonistic activity with respect to calcium channels and anti-hypertensive activity and can be used in medicine in treatment of diseases of cardiovascular system.EFFECT: valuable medicinal properties of compound.7 cl, 3 tbl, 5 ex
ethod for treating children at cerebrasthenic syndrome // 2290869
FIELD: medicine, neurology.SUBSTANCE: the present innovation deals with treating cerebrasthenic syndrome (CS) due to carrying out therapy at taking into account the data of a child's complex inspection. At bioelectric cerebral activity a rest being under 40 mcV and impossibility to reconstruct its background values after functional loadings during 3 min by EEG, deviation of cerebral neuromediator supply by 10% and more, affected fermentative activity along with decreased utilization of glucose and creatine phosphate synthesis according to electromagnetic cerebral scanning (EMS) data it is possible to establish CS as a result of oxygen-dependent cerebral hypoergia to introduce amino acids, enzymes, iron preparations, vitamins, hepatoprotectors during 1-mo-long period; then - nootropes and sedative preparations and then comes transcranial micropolarizations (TCMP) along the intake of antihypoxants and vitamin and microelements complexes. Such therapeutic courses should be repeated twice or thrice at interval being not less than 2 mo at keeping soft daily schedule. In case of analogous EEG alterations, the deficiency of initial pulse circulation in carotid and vertebral-basilary (VB) basin being not less than 10%, and during carrying out functional samples - up to 55-75% against the norm, the signs of venous outflow difficulties at REG and USDG, and decreased activity of neurons by above 20% according EMS data it is possible to state upon CS at VB failure and the risk for syncopic states; also, in therapy one should additionally apply vasoactive, spasmolytic and diuretic preparations for 1 mo, and after TCMP the course of resolution therapy should be conducted. In case of instability of vertebro-motor segments and ligamentous-muscular apparatus of cervical vertebrae and rotation subluxations C1 or C2 at wave deviation being above 0.2 mm according to EMS data, and at availability of vascular abnormality of brain or neck it is necessary to fulfill MRT at vascular program. In case of pronounced instability, and/or functional blocks at the level of C1-C5, and/or shifts of disks or vertebral bodies it is important to conduct manual therapy of cervical department at "soft techniques", except those at inborn abnormality of cranio-vertebral area. The innovation provides rapid and stable effect due to differentiating complex therapy at taking into account all the links of etiopathogenesis.EFFECT: higher efficiency of therapy.4 cl, 3 ex
Composition with prolonged effect possessing anti-hypertensive and diuretic activity and method for its preparing // 2288713
FIELD: medicine, chemical-pharmaceutical industry, pharmacy.SUBSTANCE: invention proposes a composition possessing anti-hypertensive and diuretic activity with prolonged release of an active component. The composition comprises an envelope-covered core comprising indapamide as an active component and ludipress, hydroxypropylmethylcellulose, aerosil and stearate as accessory components. The core is covered by a film-forming envelope that is based on hydroxypropylmethylcellulose preferably and comprising additionally polyethylene glycol, glycerol, talc, titanium dioxide and lactose. Method for preparing the novel composition involves mixing indapamide and accessory components followed by forming the prepared mixture to form the core of required configuration and size and applying the envelope. The composition is characterized by continuous release of indapamide, high fracture and abrasion strength, stability of active component during storage with the fitness time above 2 years.EFFECT: improved preparing method, improved and valuable properties of composition.9 cl, 2 tbl, 4 ex
Pharmaceutical formulation of prolonged action with diuretic, vasodilatation and hypotensive activity, and method for production thereof // 2286150
FIELD: pharmaceutical industry, in particular, in particular solid pharmaceutical formulations useful in treatment of arterial hypertension and chronic heart failure.SUBSTANCE: claimed formulation comprises core containing (mass %): inapamide 0.3-2.0; colloidal silica 0.1-2.5; hydroxypropyl cellulose 8-35; vinyl pyrrolidone-vinyl acetate copolymer 1.8-4.5; magnesium stearate 0.1-1.0; lactose 15.0-55.0; and balance: microcrystalline cellulose; and sell dissolvable in stomach and containing (mass %) polyethylene glycol 10.0-17.0; titanium dioxide 11.5-20.5; talk 1.8-6.3; and balance hydroxypropylmethyl cellulose. Method for production of said formulation also is provided.EFFECT: Agent with gradual releasing of active ingredient; tablets with increased mechanical strength; preparation of improved quality in storage process.3 cl, 1 tbl, 2 ex

Drops nasal, bresolin with vasoconstrictors, anti-inflammatory and anti-edematous action // 2212235
The invention relates to the field of medicine and for the preparation of Bresolin drops nasal 0.06% and 0.1% for the treatment of diseases of the nose and throat
Pharmaceutical composition having antihypertensive and a diuretic, and how you can get // 2201751
The invention relates to medicine, specifically to pharmaceutical compositions comprising as active ingredient indapamide, and may find application in the treatment of hypertension and to prevent the delay of sodium and water in the body in chronic heart failure
Outside a decongestant // 2194517
The invention relates to medicine and can be used for the manufacture of therapeutic and cosmetic products in the form of ointments, creams, emulsions, lotions, gels, used as decongestants tools
 
2550859.
Up!